Showing 1 - 10 of 87
Following the publication of The Legal 500 UK 2022, we are proud to announce that the firm has once again achieved impressive rankings and recognition within the latest guide to leading law firms and lawyers.
We are pleased to have strengthened our London team with the appointment of partner Simon Durkin, formerly at Weightmans.
We are pleased to again report a record turnover of £264m, an increase of 11% on the previous year (£238m).We have also increased the number of fee earners globally by 10%, taking the firm’s overall headcount to in excess of 2,300
Regulatory compliance in unprecedented times: how to adapt but stay on track - a guide for the European life sciences industry
The COVID-19 pandemic has had an unprecedented impact on stakeholders in the UK and EU’s life sciences industry - from companies, to third parties, governments, regulators and insurers.
We are pleased to announce that the publication of the 2021 edition of The Legal 500 Europe, Middle East and Africa has seen us build on our 2020 achievements.
In this Q&A, Ian Kimber, Emeritus Professor of Toxicology in the Faculty of Biology, Medicine and Health at the University of Manchester, provides an immunological perspective on current issues impacting upon the life sciences sector, ranging from recently approved cancer drugs to COVID-19 vaccines.
The vulnerabilities of the life science supply chain are at the forefront of everyone’s minds, but, behind the headlines, how is the pandemic affecting attitudes to risk?
2020 was a challenging year globally. However, the start of 2021 has welcomed the rapid roll out of the breakthrough COVID-19 vaccines in the UK, a ray of hope for a way out of the pandemic. Over 20 million people in the UK have already been given vaccine doses, with the hope that the majority of the UK adult population will be vaccinated by the end of 2021.
The outcome of two Canadian product class actions in 2020 signal hurdles claimants may face around the globe in 2021 in alleging adverse health effects in mass tort claims involving products for consumption such as medical cannabis, other pharmaceutical products and food.
This report examines the key features of the Directive of the European Parliament and of the European Council on representative actions for the protection of the collective interests of consumers and its wider impact on consumer-led litigation across Europe, including comparative insights into national class action mechanisms in the United Kingdom, Belgium, Denmark, France, Portugal, Spain and Ireland.